GenMark Diagnostics (GNMK) Prices 7.254M Share Common Offering at $9.65/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Caribou Biosciences to halt CAR-T programs, explore sale
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- Francis Halzen wins Nobel physics prize for Antarctic 'ghost particle' hunt
GenMark Prices Public Offering of Common Stock
May 6, 2020 11:01 PM EDTCARLSBAD, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (GenMark or the Company), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care, today announced the pricing of its previously announced underwritten public offering of 7,253,886 shares of its common stock at a public offering price of $9.65 per share. The gross proceeds to GenMark, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $70.0 million. The offering is expected to close on... More



